Edition:
India

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.80USD
23 Nov 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.80
Open
$4.89
Day's High
$5.01
Day's Low
$4.78
Volume
95,199
Avg. Vol
83,709
52-wk High
$5.99
52-wk Low
$2.50

Latest Key Developments (Source: Significant Developments)

Chromadex Q2 Loss Per Share $0.14
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Chromadex Corp ::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.14.Q2 SALES $11.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $10.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.  Full Article

Pioneer Step Holdings Limited Reports 9.6 Percent Stake In Chromadex As Of May 9
Monday, 13 May 2019 

May 13 (Reuters) - Pioneer Step Holdings Ltd::PIONEER STEP HOLDINGS LIMITED REPORTS 9.6 PERCENT STAKE IN CHROMADEX CORP AS OF MAY 9, 2019 - SEC FILING.PIONEER STEP HOLDINGS LIMITED - HAD PREVIOUSLY REPORTED 8.1 PERCENT STAKE IN CHROMADEX CORP AS OF NOV 17, 2017.  Full Article

Chromadex Corporation Reports 2018 Financial Results
Friday, 8 Mar 2019 

March 7 (Reuters) - Chromadex Corp ::ORATION REPORTS 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.15.Q4 SALES $9.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.1 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.CONTINUE TO EXPECT COMPANY TO BE CASH FLOW BREAKEVEN BY Q4 OF 2019 OR EARLY 2020.  Full Article

Chromadex And Nestlé Health Science Sign Global Commercial License And Supply Deal
Friday, 21 Dec 2018 

Dec 20 (Reuters) - Chromadex Corp ::CHROMADEX CORP. AND NESTLÉ HEALTH SCIENCE ENTER GLOBAL COMMERCIAL LICENSE AND SUPPLY AGREEMENT FOR TRU NIAGEN®.CHROMADEX - AGREEMENT PROVIDES NHSC EXCLUSIVE RIGHT TO INCLUDE CO'S PATENTED NICOTINAMIDE RIBOSIDE INGREDIENT TRU NIAGEN IN NHSC BRANDED MEDICAL NUTRITION.CHROMADEX CORP - AGREEMENT PROVIDES NHSC CO-EXCLUSIVE RIGHTS TO INCLUDE TRU NIAGEN IN CERTAIN PRODUCTS WITHIN CONSUMER HEALTH CATEGORY.CHROMADEX CORP - UNDER TERMS OF AGREEMENT, NHSC WILL MAKE AN UPFRONT PAYMENT OF $4 MILLION.CHROMADEX - UNDER AGREEMENT CO WILL RECEIVE CERTAIN COMMERCIAL MILESTONE PAYMENTS RELATED TO SALE OF TRU NIAGEN® TO NHSC AS WELL AS TIERED ROYALTIES.  Full Article

BRIEF-Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models

* CHROMADEX AND THE NIH-NIAID ROCKY MOUNTAIN LABORATORIES ANNOUNCE STUDY TO ASSESS THE THERAPEUTIC POTENTIAL OF NIAGEN® IN COVID-19 ANIMAL MODELS